BTX161 - ≥98% , CAS No.2052301-24-1

CAS: 2052301-24-1 Cat. No.: B646408 Formule: C₁₅H₁₆N₂O₃ Poids moléculaire: 272.30

GRADE & PURITY ≥98%

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Vue d’ensemble

BTX161, a Thalidomide analog, is a potent CKIα degrader. BTX161 mediates degradation of CKIα better than Lenalidomide in human AML cells and activates DNA damage response (DDR) and p53, while stabilizing the p53 antagonist MDM2.

In Vitro

BTX161 (25 μM; 4 hours; MV4-11 cells) upregulates all the Wnt targets including MYC and did not affect MDM2 mRNA expression. BTX161 (10 μM; 6 hours; MV4-11 cells), on its own, augmented p53 and MDM2 protein expression, yet in combination with THZ1, and particularly with both THZ1 and CDK9, further augmented p53 and induced maximal caspase 3 activation. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Form:Solid

Specifications

Spécifications et pureté

≥98%

Mécanismes biochimiques et physiologiques

BTX161, a Thalidomide analog, is a potent CKIα degrader. BTX161 mediates degradation of CKIα better than Lenalidomide in human AML cells and activates DNA damage response (DDR) and p53, while stabilizing the p53 antagonist MDM2.

Conditions de stockage de stockage

Store at -20°C

Expédié en

Ice chest + Ice pads

Ce produit nécessite l'expédition en chaîne froide. Les services terrestres et autres services économiques ne sont pas disponibles.

Type d'action

INHIBITOR

Pureté

≥98%

Noms et identifiants

• Poids moléculaire: 272.30

Propriétés chimiques et physiques

• Solubilité: DMSO : 25 mg/mL (91.81 mM; ultrasonic and warming and heat to 60°C)